Revenue
2019
2020
2021
2022
Mauna Kea Technologies (MKEA)
Price—Loading quote
Financial statements
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue | €7.5M | €7.7M | €6.5M | €7.4M |
| Gross profit | €5.5M | €5.7M | €4.4M | €5.2M |
| Gross margin | 73.20% | 74.17% | 67.09% | 69.59% |
| Research & development | €4.1M | €3.3M | €3.2M | €3.2M |
| Operating expenses | €17.1M | €19.9M | €19.9M | €21.5M |
| Operating income | −€9.1M | −€12.2M | −€11.8M | −€13.0M |
| Operating margin | −121.18% | −158.68% | −181.06% | −175.32% |
| EBITDA | −€8.1M | −€10.0M | N/A | N/A |
| EBITDA margin | −107.88% | −130.29% | N/A | N/A |
| Net income | −€11.2M | −€13.4M | −€12.8M | −€15.3M |
| Net profit margin | −149.49% | −174.61% | −196.00% | −205.52% |
| Basic EPSper basic share | -€0.25 | -€0.35 | -€0.42 | -€0.60 |
Owners
Reported shareholders and owner groups
17.00%of company shares
Telix PharmaceuticalsSource updated Sep 18, 2026
View holders
| Holder | Ownership |
|---|---|
| 17.00%Sep 18, 2026 | |
| 16.00%Sep 18, 2026 | |
| 10.00%Sep 18, 2026 | |
| 2.00%Sep 18, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026